Literature DB >> 8633673

Conization for cervical intraepithelial neoplasia is followed by disappearance of human papillomavirus deoxyribonucleic acid and a decline in serum and cervical mucus antibodies against human papillomavirus antigens.

K Elfgren1, P Bistoletti, L Dillner, J M Walboomers, C J Meijer, J Dillner.   

Abstract

OBJECTIVE: Our purpose was to investigate whether conization for cervical intraepithelial neoplasia eliminates human papillomavirus deoxyribonucleic acid and effects the levels of serum and cervical mucus antibodies against human papillomavirus antigens. STUDY
DESIGN: Analysis of paired cervical brush and serum samples taken from 23 women with cervical intraepithelial neoplasia before and 16 to 27 months after conization was performed for presence of human papillomavirus deoxyribonucleic acid by polymerase chain reaction and for human papillomavirus antibodies by enzyme-linked immunosorbent assay.
RESULTS: Four women had recurrent cervical intraepithelial neoplasia, whereas 19 women were disease free. Eighteen of 23 women were positive for human papillomavirus deoxyribonucleic acid before treatment. At follow-up only the 4 women with recurrent cervical intraepithelial neoplasia were positive. Serum immunoglobulin G levels and A levels and immunoglobulin A levels in cervical mucus against most of the tested human papillomavirus antigens had declined at follow-up.
CONCLUSIONS: Human papillomavirus deoxyribonucleic acid was regularly eliminated and human papillomavirus antibody levels, especially local immunoglobulin A, declined after efficient treatment, suggesting that conization may be effective for treating the underlying human papillomavirus infection.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8633673     DOI: 10.1016/s0002-9378(96)70330-7

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  16 in total

Review 1.  Cervical cytology after 2000: where to go?

Authors:  C J Meijer; J M Walboomers
Journal:  J Clin Pathol       Date:  2000-01       Impact factor: 3.411

2.  Screening for cervical cancer: should we test for infection with high-risk HPV?

Authors:  C J Meijer; P J Snijders; A J van den Brule
Journal:  CMAJ       Date:  2000-09-05       Impact factor: 8.262

3.  HPV testing in cervical screening.

Authors:  J Cuzick
Journal:  Sex Transm Infect       Date:  1998-08       Impact factor: 3.519

4.  Longitudinal study of patients after surgical treatment for cervical lesions: detection of HPV DNA and prevalence of HPV-specific antibodies.

Authors:  R Tachezy; I Mikysková; V Ludvíková; L Rob; T Kucera; V Slavík; A Beková; H Robová; M Pluta; E Hamsíková
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-08       Impact factor: 3.267

5.  Comparison between the Hybrid Capture II test and a PCR-based human papillomavirus detection method for diagnosis and posttreatment follow-up of cervical intraepithelial neoplasia.

Authors:  Anna Söderlund-Strand; Per Rymark; Pia Andersson; Joakim Dillner; Lena Dillner
Journal:  J Clin Microbiol       Date:  2005-07       Impact factor: 5.948

Review 6.  The incidence of human papillomavirus infection following treatment for cervical neoplasia: a systematic review.

Authors:  Anne F Rositch; Heidi M Soeters; Tabatha N Offutt-Powell; Bradford S Wheeler; Sylvia M Taylor; Jennifer S Smith
Journal:  Gynecol Oncol       Date:  2014-01-07       Impact factor: 5.482

Review 7.  Patterns of persistent HPV infection after treatment for cervical intraepithelial neoplasia (CIN): A systematic review.

Authors:  Sarah R Hoffman; Tam Le; Alexandre Lockhart; Ayodeji Sanusi; Leila Dal Santo; Meagan Davis; Dana A McKinney; Meagan Brown; Charles Poole; Corinne Willame; Jennifer S Smith
Journal:  Int J Cancer       Date:  2017-02-27       Impact factor: 7.396

8.  Cervical mucus antibodies against human papillomavirus type 16, 18, and 33 capsids in relation to presence of viral DNA.

Authors:  Z Wang; B G Hansson; O Forslund; L Dillner; M Sapp; J T Schiller; B Bjerre; J Dillner
Journal:  J Clin Microbiol       Date:  1996-12       Impact factor: 5.948

9.  Does HPV-status 6-12 months after treatment of high grade dysplasia in the uterine cervix predict long term recurrence?

Authors:  Björn Strander; Walter Ryd; Keng-Ling Wallin; Bengt Wärleby; Biying Zheng; Ian Milsom; Baback Gharizadeh; Nader Pourmand; Agneta Andersson-Ellström
Journal:  Eur J Cancer       Date:  2007-07-05       Impact factor: 9.162

Review 10.  Posttreatment human papillomavirus testing for recurrent cervical intraepithelial neoplasia: a systematic review.

Authors:  Benjamin K S Chan; Joy Melnikow; Christina A Slee; Rose Arellanes; George F Sawaya
Journal:  Am J Obstet Gynecol       Date:  2009-01-24       Impact factor: 8.661

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.